Stavia Tablet 100 mg (Sitagliptin Phosphate Hydrate)
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Dong Sung Pharmaceutical Co., Ltd.
MFDS item code 201502384 · Approved 2015.04.21
This product's status changed to Expired on 2025.04.21. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to assist in blood sugar control in patients with type 2 diabetes. It can be administered alone or in conjunction with dietary and exercise therapy, and may be combined with metformin when blood sugar control is difficult with monotherapy in patients with no prior medication experience. Additionally, it is administered in combination when blood sugar control is insufficient with mon therapies such as sulfonylurea, metformin, thiazolidinedione, or insulin. If blood sugar control remains challenging when multiple medications are used, this drug can be added to enhance treatment efficacy. It helps improve blood sugar control and assists in diabetes management.
This medicine is administered at a dose of 100 mg once daily, either as monotherapy or in combination therapy; the maximum daily dose is 100 mg. It may be taken with or without food. When administered in combination with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dose adjustment is required according to renal function, renal function should be assessed before treatment with this medicine and periodically thereafter. 1. No dose adjustment is required in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.
This medication may cause severe allergic reactions in some patients; therefore, if symptoms such as skin rash or difficulty breathing occur, stop taking it immediately and consult a doctor. This medication can induce acute pancreatitis, a severe inflammation of the pancreas; hence, any symptoms such as abdominal pain, nausea, or vomiting should prompt immediate medical attention. Patients with type 1 diabetes or diabetic ketoacidosis should not take this medication, and those allergic to this medication or its components should avoid it. Patients with reduced kidney function need dose adjustments for this medication, thus regular kidney function tests should be conducted, and the drug should be taken according to the doctor's instructions. In clinical trials, adverse effects have been reported, primarily upper respiratory infections, nasopharyngitis, and headaches, and the risk of hypoglycemia may increase when used in combination with other diabetes medications, so caution is needed. When taking this medication with insulin or sulfonylurea, hypoglycemic symptoms may occur, hence blood sugar should be checked frequently, and dose adjustments may be necessary. If severe joint pain or skin blistering symptoms occur, the use of this medication should be stopped immediately, and medical staff should be informed. Pregnant or nursing women are advised against using this medication, and safety in children or adolescents under 18 has not been established. Elderly patients may experience decreased kidney function; therefore, kidney function should be regularly evaluated before and after taking this medication. In the case of overdose, general treatment measures should be followed, and dialysis may be considered if necessary, so strict adherence to the prescribed dosages is crucial. This medication has relatively few drug interactions, but it should be taken according to doctor's instructions when used with cyclosporine or digoxin. If unusual symptoms arise while taking this medication, inform medical staff immediately to receive appropriate measures.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container that is air-tight and best kept at ambient temperatures between 1 to 30 degrees Celsius. This way, the medication's effectiveness will be well maintained and degradation prevented.
Beige, round, biconvex film-coated tablet
28 tablets/box [(14 tablets/PTPX2)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Dong Sung Pharmaceutical Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.